Is Neurosense Therapeutics Stock a Good Investment?
Neurosense Therapeutics Investment Advice | NRSN |
- Examine Neurosense Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Neurosense Therapeutics' leadership team and their track record. Good management can help Neurosense Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Neurosense Therapeutics' business and its evolving consumer preferences.
- Compare Neurosense Therapeutics' performance and market position to its competitors. Analyze how Neurosense Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Neurosense Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Neurosense Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Neurosense Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Neurosense Therapeutics is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Unstable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Neurosense Therapeutics Stock
Researching Neurosense Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 31.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.76. Neurosense Therapeutics had not issued any dividends in recent years.
To determine if Neurosense Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Neurosense Therapeutics' research are outlined below:
| Neurosense Therapeutics generated a negative expected return over the last 90 days | |
| Neurosense Therapeutics has some characteristics of a very speculative penny stock | |
| Neurosense Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (11.28 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neurosense Therapeutics currently holds about 10.37 M in cash with (8.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Neurosense Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 31.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Market Alert NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug |
Neurosense Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Neurosense Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Neurosense Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact Neurosense Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Neurosense Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-03-29 | 2023-12-31 | -0.2 | -0.16 | 0.04 | 20 | ||
2023-06-01 | 2023-03-31 | -0.29 | -0.33 | -0.04 | 13 | ||
2021-12-10 | 2021-09-30 | -0.21 | -0.25 | -0.04 | 19 | ||
2022-05-31 | 2022-03-31 | -0.18 | -0.24 | -0.06 | 33 | ||
2024-06-24 | 2024-03-31 | -0.2 | -0.35 | -0.15 | 75 | ||
2024-08-28 | 2024-06-30 | -0.18 | -0.02 | 0.16 | 88 | ||
2023-08-16 | 2023-06-30 | -0.28 | -0.44 | -0.16 | 57 | ||
2023-11-28 | 2023-09-30 | -0.24 | 0.1 | 0.34 | 141 |
Know Neurosense Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Neurosense Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neurosense Therapeutics backward and forwards among themselves. Neurosense Therapeutics' institutional investor refers to the entity that pools money to purchase Neurosense Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Cwm, Llc Duplicate | 2024-12-31 | 1000 | Qube Research & Technologies | 2024-09-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 0.0 | Citadel Advisors Llc | 2024-12-31 | 254 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 102.6 K | Jane Street Group Llc | 2024-12-31 | 64.6 K | Hrt Financial Llc | 2024-12-31 | 64.4 K | Xtx Topco Ltd | 2024-12-31 | 41.9 K | Meitav Dash Investments Ltd | 2024-12-31 | 40 K | Stratos Wealth Partners, Ltd | 2024-12-31 | 20 K | Commonwealth Equity Services Inc | 2024-12-31 | 16.2 K |
Neurosense Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 25.09 M.Market Cap |
|
Neurosense Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.66) | (3.84) | |
| Return On Capital Employed | 38.32 | 40.23 | |
| Return On Assets | (3.66) | (3.84) | |
| Return On Equity | 4.85 | 5.10 |
Determining Neurosense Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Neurosense Therapeutics is a good buy. For example, gross profit margin measures Neurosense Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Neurosense Therapeutics' profitability and make more informed investment decisions.
Evaluate Neurosense Therapeutics' management efficiency
Neurosense Therapeutics has return on total asset (ROA) of (2.1964) % which means that it has lost $2.1964 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.9484) %, meaning that it created substantial loss on money invested by shareholders. Neurosense Therapeutics' management efficiency ratios could be used to measure how well Neurosense Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Neurosense Therapeutics' Return On Capital Employed is very stable compared to the past year. As of the 25th of March 2025, Return On Equity is likely to grow to 5.10, while Return On Tangible Assets are likely to drop (3.84). At this time, Neurosense Therapeutics' Total Assets are very stable compared to the past year. As of the 25th of March 2025, Net Tangible Assets is likely to grow to about 10.9 M, while Non Current Assets Total are likely to drop about 154 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.16) | (0.15) | |
| Tangible Book Value Per Share | (0.16) | (0.15) | |
| Enterprise Value Over EBITDA | (0.69) | (0.73) | |
| Price Book Value Ratio | (6.57) | (6.24) | |
| Enterprise Value Multiple | (0.69) | (0.73) | |
| Price Fair Value | (6.57) | (6.24) | |
| Enterprise Value | 12.3 M | 12.9 M |
Leadership at Neurosense Therapeutics emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Beta 1.256 |
Basic technical analysis of Neurosense Stock
As of the 25th of March, Neurosense Therapeutics secures the Downside Deviation of 3.57, risk adjusted performance of 0.0875, and Mean Deviation of 3.13. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neurosense Therapeutics, as well as the relationship between them.Neurosense Therapeutics' Outstanding Corporate Bonds
Neurosense Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Neurosense Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Neurosense bonds can be classified according to their maturity, which is the date when Neurosense Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Neurosense Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Neurosense Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0875 | |||
| Market Risk Adjusted Performance | (1.98) | |||
| Mean Deviation | 3.13 | |||
| Semi Deviation | 3.05 | |||
| Downside Deviation | 3.57 | |||
| Coefficient Of Variation | 1136.79 | |||
| Standard Deviation | 4.7 | |||
| Variance | 22.06 | |||
| Information Ratio | 0.0936 | |||
| Jensen Alpha | 0.3958 | |||
| Total Risk Alpha | 0.5931 | |||
| Sortino Ratio | 0.1231 | |||
| Treynor Ratio | (1.99) | |||
| Maximum Drawdown | 31.95 | |||
| Value At Risk | (5.41) | |||
| Potential Upside | 6.31 | |||
| Downside Variance | 12.75 | |||
| Semi Variance | 9.31 | |||
| Expected Short fall | (4.24) | |||
| Skewness | 2.09 | |||
| Kurtosis | 8.89 |
| Risk Adjusted Performance | 0.0875 | |||
| Market Risk Adjusted Performance | (1.98) | |||
| Mean Deviation | 3.13 | |||
| Semi Deviation | 3.05 | |||
| Downside Deviation | 3.57 | |||
| Coefficient Of Variation | 1136.79 | |||
| Standard Deviation | 4.7 | |||
| Variance | 22.06 | |||
| Information Ratio | 0.0936 | |||
| Jensen Alpha | 0.3958 | |||
| Total Risk Alpha | 0.5931 | |||
| Sortino Ratio | 0.1231 | |||
| Treynor Ratio | (1.99) | |||
| Maximum Drawdown | 31.95 | |||
| Value At Risk | (5.41) | |||
| Potential Upside | 6.31 | |||
| Downside Variance | 12.75 | |||
| Semi Variance | 9.31 | |||
| Expected Short fall | (4.24) | |||
| Skewness | 2.09 | |||
| Kurtosis | 8.89 |
Consider Neurosense Therapeutics' intraday indicators
Neurosense Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Neurosense Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 6690.14 | |||
| Daily Balance Of Power | 0.2 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 1.09 | |||
| Day Typical Price | 1.08 | |||
| Period Momentum Indicator | 0.01 |
Neurosense Stock media impact
Far too much social signal, news, headlines, and media speculation about Neurosense Therapeutics that are available to investors today. That information is available publicly through Neurosense media outlets and privately through word of mouth or via Neurosense internal channels. However, regardless of the origin, that massive amount of Neurosense data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Neurosense Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Neurosense Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Neurosense Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Neurosense Therapeutics alpha.
Neurosense Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Neurosense Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Neurosense Therapeutics Corporate Management
| Sharon Vered | Global CMC | Profile | |
| Diana Shtossel | Head Affairs | Profile | |
| Or Eisenberg | Chief Officer | Profile | |
| Nedira SalzmanFrenkel | Global Devel | Profile | |
| Yael Barak | Head Compliance | Profile | |
| Alon BenNoon | CEO CoFounder | Profile | |
| Hagit Binder | VP Operations | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurosense Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Neurosense Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.